cyclosporine + ticagrelor

Cyclosporine + ticagrelor is a combination of two pharmaceutical agents: **cyclosporine**, an immunosuppressive agent used primarily to prevent organ transplant rejection, and **ticagrelor**, an oral, reversible P2Y12 receptor antagonist used as an antiplatelet agent for acute coronary syndrome. Both drugs are **small molecules** and act via distinct but interacting mechanisms. When co-administered, there is a significant pharmacokinetic interaction due to cyclosporine’s potent inhibition of P-glycoprotein (P-gp) and CYP3A4, leading to increased plasma concentrations of ticagrelor and its active metabolite (AR-C124910XX). This can result in heightened risk for adverse effects such as life-threatening bleeding. Additionally, ticagrelor can modestly increase blood concentrations of cyclosporine. The combination does not have unique indications beyond those of the individual drugs and is not a branded fixed-dose product; its clinical use is limited by safety concerns stemming from their drug–drug interaction[1][4][5][6].